Next Article in Journal
Acidification is an Essential Process of Cold Atmospheric Plasma and Promotes the Anti-Cancer Effect on Malignant Melanoma Cells
Previous Article in Journal
Control of Tyrosine Kinase Signalling by Small Adaptors in Colorectal Cancer
Previous Article in Special Issue
Prospect of Plasmacytoid Dendritic Cells in Enhancing Anti-Tumor Immunity of Oncolytic Herpes Viruses
Article Menu
Issue 5 (May) cover image

Export Article

Open AccessReview

Unleashing Tumour-Dendritic Cells to Fight Cancer by Tackling Their Three A’s: Abundance, Activation and Antigen-Delivery

1
Myeloid Cell Immunology Lab, VIB Center for Inflammation Research, 1050 Brussels, Belgium
2
Lab of Cellular and Molecular Immunology, Vrije Universiteit Brussel, 1050 Brussels, Belgium
*
Author to whom correspondence should be addressed.
Cancers 2019, 11(5), 670; https://doi.org/10.3390/cancers11050670
Received: 1 March 2019 / Revised: 22 April 2019 / Accepted: 10 May 2019 / Published: 14 May 2019
(This article belongs to the Special Issue Tumour Associated Dendritic Cells)
  |  
PDF [682 KB, uploaded 14 May 2019]
  |  

Abstract

Recent advances in cancer immunotherapy have mainly focused on re-activating T-cell responses against cancer cells. However, both priming and activation of effector T-cell responses against cancer-specific antigens require cross-talk with dendritic cells (DCs), which are responsible for the capturing, processing and presentation of tumour-(neo)antigens to T cells. DCs consequently constitute an essential target in efforts to generate therapeutic immunity against cancer. This review will discuss recent research that is unlocking the cancer-fighting potential of tumour-infiltrating DCs. First, the complexity of DCs in the tumour microenvironment regarding the different subsets and the difficulty of translating mouse data into equivalent human data will be briefly touched upon. Mainly, possible solutions to problems currently faced in DC-based cancer treatments will be discussed, including their infiltration into tumours, activation strategies, and antigen delivery methods. In this way, we hope to put together a broad picture of potential synergistic therapies that could be implemented to harness the full capacity of tumour-infiltrating DCs to stimulate anti-tumour immune responses in patients. View Full-Text
Keywords: dendritic cells; tumour-associated dendritic cells; immunotherapy; DC-therapy; DC-vaccinations dendritic cells; tumour-associated dendritic cells; immunotherapy; DC-therapy; DC-vaccinations
Figures

Figure 1

This is an open access article distributed under the Creative Commons Attribution License which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited (CC BY 4.0).
SciFeed

Share & Cite This Article

MDPI and ACS Style

Murgaski, A.; Bardet, P.M.R.; Arnouk, S.M.; Clappaert, E.J.; Laoui, D. Unleashing Tumour-Dendritic Cells to Fight Cancer by Tackling Their Three A’s: Abundance, Activation and Antigen-Delivery. Cancers 2019, 11, 670.

Show more citation formats Show less citations formats

Note that from the first issue of 2016, MDPI journals use article numbers instead of page numbers. See further details here.

Related Articles

Article Metrics

Article Access Statistics

1

Comments

[Return to top]
Cancers EISSN 2072-6694 Published by MDPI AG, Basel, Switzerland RSS E-Mail Table of Contents Alert
Back to Top